BioRestorative Closes $5M Equity Offering to Fund Stem Cell Pipeline
BioRestorative raised $5M through equity offering to advance stem cell therapies, including BRTX-100 for spine disease and metabolic disorder research.
BRTXclinical trialsregenerative medicine